Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

342. Review: self monitoring increases the efficacy and safety of anticoagulant therapy

Review: self monitoring increases the efficacy and safety of anticoagulant therapy Review: self monitoring increases the efficacy and safety of anticoagulant therapy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: self monitoring increases the efficacy and safety of anticoagulant therapy Article Text Therapeutics Review: self monitoring increases the efficacy and safety of anticoagulant therapy Free John Spandorfer , MD Statistics from Altmetric.com No Altmetric data available for this article. Heneghan C, Alonso-Coello P, Garcia-Alamino

Evidence-Based Medicine (Requires free registration)2007

343. What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve?

What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? BestBets: What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? Report By: Andrew Bayliss, Peter Faber, Joel (...) (caged-ball) valves Overall similar to the ACCP recommendations although no comments on combination with aspirin or dipyridamole Lowe et al, 1999 Scotland Scottish Intercollegiate Guidelines Guidelines based on available cohort & RCT's (Level Ib-IV) Need for anticoagulation therapy Patients with mechanical heart valves require long-term warfarin therapy (level IIa, IIb, III evidence) Varying levels of evidence Significant amount of evidence remains "expert opinion" Recommendations for first

BestBETS2007

344. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.

Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. BACKGROUND: Non-valvular atrial fibrillation (AF) carries an increased risk of stroke mediated by embolism of stasis-precipitated thrombi originating in the left atrial appendage. Both oral anticoagulants and antiplatelet agents have proven effective for stroke prevention in most patients at high risk for vascular events (...) , but primary stroke prevention in patients with non-valvular AF potentially merits separate consideration because of the suspected cardio-embolic mechanism of most strokes in AF patients. OBJECTIVES: To characterize the relative effect of long-term oral anticoagulant treatment compared with antiplatelet therapy on major vascular events in patients with non-valvular AF and no history of stroke or transient ischemic attack (TIA). SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register (June

Cochrane2007

345. Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters.

Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. BACKGROUND: Central venous catheter (CVC) placement increases the risk of thrombosis in cancer patients. Thrombosis often necessitates the removal of the CVC, resulting in treatment delays and thrombosis related morbidity and mortality. OBJECTIVES: To evaluate the efficacy and safety of anticoagulation in reducing venous thromboembolic (VTE) events in cancer patients with CVC. SEARCH STRATEGY (...) : A comprehensive search for studies of anticoagulation in cancer patients up to January 2006 was conducted in the following databases: The Cochrane Central Register of Controlled Trials ( CENTRAL), MEDLINE, EMBASE and ISI the Web of Science. SELECTION CRITERIA: Randomized controlled trials (RCTs) comparing unfractionated heparin (UFH), low molecular weight heparin (LMWH), vitamin K antagonists (VKA), fondaparinux or ximelagatran to no intervention or placebo in cancer patients with a CVC or comparing two

Cochrane2007

346. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation.

Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. BACKGROUND: Basic research and clinical studies have generated the hypothesis that anticoagulation may improve survival in patients with cancer through an antitumour effect in addition to the antithrombotic effect. OBJECTIVES: To evaluate the efficacy and safety of heparin (including unfractionated heparin (UFH) and low molecular weight heparin (LMWH)) and fondaparinux to (...) improve survival of patients with cancer. SEARCH STRATEGY: A comprehensive search for studies of anticoagulation in cancer patients including (1) A January 2007 electronic search of the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and ISI the Web of Science; (2) Hand search of the American Society of Clinical Oncology and of the American Society of Hematology; (3) Checking of references of included studies; and (4) Use of "related article" feature

Cochrane2007

347. WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.

WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. BACKGROUND: Atrial fibrillation (AF) carries a high risk of stroke and other thromboembolic events. Appropriate use of drugs to prevent thromboembolism in patients with AF involves comparing the patient's risk of stroke to the risk of hemorrhage from medication use. OBJECTIVES: To quantify risk of stroke, major hemorrhage and death from using medications that have been rigorously evaluated

Cochrane2007

348. WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery.

WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. BACKGROUND: The reported overall risk of deep venous thrombosis in gynaecological surgery ranges from 7 to 45%. Fatal pulmonary embolism is estimated to occur in nearly 1% of these women. Pharmaceutical interventions are one possible prophylactic measure for preventing emboli in women undergoing major gynaecological surgery. Agents include unfractionated heparin (low -dose (...) increase in injection site haematomas associated with heparin compared to placebo (OR 0.30, 95% CI 0.10 to 0.89). AUTHORS' CONCLUSIONS: Women, undergoing major gynaecological surgery and without contraindications to anticoagulants should be offered thromboprophylaxis. Evidence suggests that UH and LMWH are equally as effective in preventing DVT and the one trial available suggests that warfarin is as effective as UH. There is no evidence as yet to suggest that warfarin, heparin or aspirin reduce

Cochrane2007

349. Is short-term anticoagulation necessary after mitral valve repair?

Is short-term anticoagulation necessary after mitral valve repair? BestBets: Is short-term anticoagulation necessary after mitral valve repair? Is short-term anticoagulation necessary after mitral valve repair? Report By: Sanjay Asopa, Anish Patel - Specialist Registrars in Cardiothoracic Surgery Search checked by Joel Dunning - Cardiothoracic Registrar RCS Institution: Wessex Cardiothoracic Unit, Southampton General Hospital Date Submitted: 21st December 2006 Date Completed: 9th May 2007 Last (...) 1980 and 1986. All patients were placed on warfarin on the third post-operative day. Warfarin was discontinued at the end of 3 months and patients were switched to antiplatelet therapy. High risk patients with predisposing factors were continued on warfarin long term basis Retrospective cohort study (level 2b) Long-term thrombo-embolic rates following mitral valve reconstruction. Of the 125 survivors without re-operation, (73 of 125) 58.4 % were on an anticoagulant or antiplatelet therapy.(34

BestBETS2007

350. Review: long term anticoagulation reduces recurrent venous thromboembolism

Review: long term anticoagulation reduces recurrent venous thromboembolism Review: long term anticoagulation reduces recurrent venous thromboembolism | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: long term anticoagulation reduces recurrent venous thromboembolism Article Text Therapeutics Review: long term anticoagulation reduces recurrent venous thromboembolism Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link below which will take

Evidence-Based Medicine (Requires free registration)2007

352. Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin.

Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. BACKGROUND: Preoperative low-molecular-weight heparin (LMWH) is often used when warfarin therapy is interrupted for surgery. OBJECTIVE: To determine the preoperative anticoagulant activity of LMWH following a standardized "bridging" regimen. DESIGN: Prospective cohort study. SETTING: Single university hospital. PATIENTS: Consecutive patients who had

Annals of Internal Medicine2007

353. Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management.

Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management. Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:005300 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries

American Association of Poison Control Centers2007

354. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications Kuderer N M, Khorana A A, Lyman G H, Francis C W (...) CRD summary The authors concluded that anticoagulants, especially low molecular weight heparin, significantly increase survival in cancer patients without venous thromboembolism, but also increase the risk of bleeding. However, anticoagulants cannot be recommended as a cancer treatment until further research confirms these results. This was a well-conducted and clearly presented review, and the authors’ conclusions are likely to be reliable. Authors' objectives To evaluate the effects

DARE.2007

355. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials

Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials Paciaroni M, Agnelli G, Micheli S, Caso V CRD summary The authors concluded that the use of early anticoagulation (...) in patients with acute ischaemic cardioembolic stroke to prevent early recurrence or to improve functional outcome is not supported by the evidence. This was a well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To evaluate the efficacy and safety of anticoagulants for the initial treatment of patients with acute cardioembolic stroke. Searching MEDLINE, EMBASE (both from 1980 to February 2006) and the Cochrane Library (Issue 1, 2006) were searched using

DARE.2007

356. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis

Self-management of oral anticoagulant therapy: a systematic review and meta-analysis Self-management of oral anticoagulant therapy: a systematic review and meta-analysis Self-management of oral anticoagulant therapy: a systematic review and meta-analysis Christensen T D, Johnsen S P, Hjortdal V E, Hasenkam J M CRD summary This review concluded that, for highly selected patients, self-management of oral anticoagulant therapy appeared to be at least as good as, and possibly better than (...) , conventional management. This conclusion may not be reliable given the quality of, and heterogeneity between, included trials and the potential publication bias. Authors' objectives To assess the efficacy and safety of self-management of oral anticoagulant therapy for patients on long-term treatment. Searching The Cochrane Central Register of Controlled Trials and PubMed were searched from 1951 to December 2005. Search terms were reported. Additional studies were sought through a review of personal files

DARE.2007

357. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients

Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients Dentali F, Douketis J D, Gianni M, Lim W, Crowther M A CRD summary This review assessed the effects of anticoagulant prophylaxis (...) in hospitalised medical patients. The authors concluded that anticoagulant prophylaxis is effective in preventing symptomatic venous thromboembolism during anticoagulant prophylaxis in at-risk hospitalised patients. This was a well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To determine the effects of anticoagulant prophylaxis in reducing clinically important outcomes in hospitalised medical patients. Searching The authors searched MEDLINE and EMBASE from

DARE.2007

358. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardivascular disease: a meta-analysis of randomized trials

Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardivascular disease: a meta-analysis of randomized trials Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardivascular disease: a meta-analysis of randomized trials Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardivascular disease (...) : a meta-analysis of randomized trials Dentali F, Douketis J D, Lim W, Crowther M CRD summary This well-conducted review compared the effectiveness and safety of oral anticoagulant (OAC) therapy plus aspirin with OAC alone. The authors concluded that, except for patients with a mechanical heart valve, the benefits of OAC therapy plus aspirin in reducing thromboembolic events were unclear and there were increased risks of major bleeding. This conclusion is likely to be reliable. Authors' objectives

DARE.2007

359. An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation

An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation Leigh J P, White R H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the clinical and economic impact of warfarin versus a second anticoagulant in hypothetical cohort of 70-year-old patients with atrial fibrillation. There was substantial variation in rates and costs of adverse events when considering all possible scenarios, but the difference in costs between the two drugs was modest. Overall, the analysis

NHS Economic Evaluation Database.2007

360. Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study

Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study Nurmohamed S A, Vervloet M G, Girbes A R, Ter Wee P M, Groeneveld A B Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the costs and effects of continuous venovenous haemofiltration (CVVH) alone with CVVH plus predilution regional citrate anticoagulation (RCA) for critically-ill patients. The authors concluded that both treatments had similar costs

NHS Economic Evaluation Database.2007